E3A Healthcare was selected for the Hong Kong Business Incubation Programme
The Hong Kong Science and Technology Parks (HKSTP) is a statutory body established by the Hong Kong SAR Government in 2001 to support companies in key technology areas such as biomedical, electronics, green technology, information and communications technology, and materials and precision engineering through research facilities, infrastructure, services and programs to help technology companies nurture ideas, innovate and grow.
As the largest high-tech R&D and business incubation base in Hong Kong, HKSTP has a number of inherent advantages in incubating and accelerating startups, including an international exchange platform and opportunities for collaboration with industry leaders. To date, the number of technology and start-up companies has increased from 700 to 1,000 in the past five years (2016-2021), with more than 17,000 practitioners in the field of innovation and technology, and has attracted many renowned research institutions and universities from home and abroad to set up laboratories in the park.
E3A Healthcarehas been selected to participate in the 3-year Incubation Programme of the Hong Kong Science and Technology Parks (HKSTP), which provides comprehensive support, including research support, mentorship and investor matching, to help technology start-ups bring their research results to market and develop their business.
So far as many as 850 incubatees have successfully graduated from the Incu-Tech programme, of which 80% are still in operation and four have applied for listing in Hong Kong. These companies are currently applying for intellectual property rights for over 1,000 R&D results and have so far received over 630 awards.
E3A HealthcareAs a Sino-Hong Kong medical technology innovation enterprise, we have personally felt the rapid development of medical science and innovation in Hong Kong and Macao Bay Area in recent years, and also benefited from the good science and innovation environment and strong industrial resources support, the company's scientific research achievements can be efficiently converted to the ground. E3A Healthcareproduct line has now comprehensively covered the whole cycle of pregnancy, delivery and childbirth for women. The first innovative self-developed product - neonatal transcutaneous jaundice meter has also been successfully launched in the domestic market, and has received good market feedback and user recognition. We have always been committed to providing higher quality medical devices and services for mothers and babies worldwide through our innovative research and development.
By successfully joining the Incu-Tech Program of Hong Kong Science and Technology Parks, we will have more opportunities to communicate with international platforms, cooperate with industry leaders, world-class equipment, and financial assistance, which we believe will greatly accelerate the transformation of our technology R&D results to the ground and bring our products to the global market.
In the future, E3A Healthcarewill continue to plough into the medical device industry and persistently promote the innovative development of domestic medical devices through independent R&D and production, so as to accelerate the completion of "import substitution" of domestic medical devices. Following the important instruction made by General Secretary Xi Jinping during his visit to Hong Kong in June this year - "to give full play to Hong Kong's own strengths, gather global innovation resources, join hands with cities in Guangdong, Hong Kong and Macao to strengthen the synergy of industry, academia and research innovation, and strive to build a global highland of science and technology innovation". It is committed to providing "IoT+SaaS" mother and baby full-cycle smart medical solutions for thousands of families worldwide.
